Potential use of acetogenins as adjuvants in the treatment of canine transmissible venereal tumor. Case report
Open Access
- 6 July 2025
- journal article
- Published by Universidad del Zulia in Revista Científica de la Facultad de Ciencias Veterinarias
- Vol. 35 (3) , 9
Abstract
Vincristine, an antimicrotubular alkaloid, is the standard treatment for transmissible venereal tumor in dogs due to its high rate of clinical remission. However, recent studies have explored its combination with natural bioactive compounds as a strategy to enhance therapeutic efficacy and reduce adverse effects. This study evaluated the clinical effectiveness of vincristine in combination with acetogenins phytochemicals derived from the leaves of Annona muricata in two female dogs with cytologically confirmed genital transmissible venereal tumor. Both patients received vincristine at a dose of 0.5 mg·m-² intravenously, once weekly for six weeks. In one of the dogs, a daily dose of 7.5 to 10 mg of acetogenins was administered from the first chemotherapy session for the initial 15 days. From the third vincristine application onward, the dose was increased to 14.5 to 20 mg·day-1 of acetogenins, divided into two oral administrations (one capsule in the morning and one in the evening) with food, and maintained for a total of four months. The dog treated with the combined protocol exhibited early tumor regression, with a significant reduction from the second week and a clinical remission of 99.85% by the end of treatment. No adverse effects associated with acetogenin administration were observed. In contrast, the dog treated with vincristine alone showed a partial response, with persistent tumor tissue at the end of the protocol. The combination of vincristine and acetogenins appears to be a promising therapeutic strategy that may enhance the efficacy of conventional transmissible venereal tumor treatment in dogs. However, these preliminary findings require validation through controlled clinical trials with a higher number of experimental units, as well as histopathological and molecular markers assessments to elucidate the underlying mechanisms of action and support the development of standardized therapeutic protocols.Keywords
This publication has 35 references indexed in Scilit:
- Controlling deltamethrin-resistant Rhipicephalus microplus with a phytoformulation of Annona muricata and Piper longumActa Tropica, 2025
- Annonaceous Acetogenins Synergistically Inhibit Hepatocellular Carcinoma with SorafenibJournal of Natural Products, 2024
- Overcoming multi drug resistance mediated by ABC transporters by a novel acetogenin- annonacin from Annona muricata L.Journal of Ethnopharmacology, 2023
- Utility of the second-generation curcumin analogue RL71 in canine histiocytic sarcomaVeterinary Research Communications, 2023
- Cryo-electron microscopy reveals how acetogenins inhibit mitochondrial respiratory complex IJournal of Biological Chemistry, 2022
- Antitumour activity of Annona muricata L. leaf methanol extracts against Ehrlich Ascites Carcinoma and Dalton’s Lymphoma Ascites mediated tumours in Swiss albino miceLibyan Journal of Medicine, 2020
- Vincristine and ivermectin combination chemotherapy in dogs with natural transmissible venereal tumor of different cyto-morphological patterns: A prospective outcome evaluationAnimal Reproduction Science, 2020
- Effect of acetogenin fraction of Annona muricata leaves on antioxidant status and some indices of benign prostatic hyperplasia in ratsRedox Report, 2020
- Annona muricata: A comprehensive review on its traditional medicinal uses, phytochemicals, pharmacological activities, mechanisms of action and toxicityArabian Journal of Chemistry, 2018
- Emerging therapeutic potential of graviola and its constituents in cancersCarcinogenesis, 2018